PSY44 A Cost Effectiveness Model for the Myeloplastic Disease in Greece. Azacitidine Versus Conventional Care Regimens
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1767
https://www.valueinhealthjournal.com/article/S1098-3015(12)03480-8/fulltext
Title :
PSY44 A Cost Effectiveness Model for the Myeloplastic Disease in Greece. Azacitidine Versus Conventional Care Regimens
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03480-8&doi=10.1016/j.jval.2012.08.1767
First page :
A516
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
1256